Revelation Biosciences, Inc. (REVB) Bundle
A Brief History of Revelation Biosciences, Inc.
Company Overview
Revelation Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious conditions. As of 2024, the company has not generated any revenue from product sales, primarily due to ongoing research and development efforts related to its product candidates: GEM-AKI, GEM-CKD, and GEM-PSI.
Financial Performance
For the nine months ended September 30, 2024, Revelation reported a net loss of $13.3 million, compared to a net income of $2.1 million for the same period in 2023. As of September 30, 2024, the company had an accumulated deficit of $38.8 million and stockholders' equity of $2.7 million. The available cash and cash equivalents stood at $6.5 million .
Recent Developments
In January 2024, the company executed a 1-for-30 reverse stock split of its common stock. Following this, on February 5, 2024, Revelation completed a public offering that raised approximately $5.4 million .
Cash Flow Analysis
The cash flows for the nine months ended September 30, 2024, showed net cash used in operating activities of $14.6 million, with cash used in investing activities amounting to $36,860. The net cash provided by financing activities was $9.2 million .
| Period | Net Loss | Cash and Cash Equivalents | Accumulated Deficit | Stockholders' Equity |
|---|---|---|---|---|
| September 30, 2024 | $13.3 million | $6.5 million | $38.8 million | $2.7 million |
| September 30, 2023 | $2.1 million (income) | Not specified | Not specified | Not specified |
Operating Expenses
Operating expenses for the nine months ended September 30, 2024, totaled $6.2 million, a slight decrease from $6.3 million in 2023. The breakdown was as follows:
| Expense Type | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Research and Development | $2.9 million | $3.1 million |
| General and Administrative | $3.3 million | $3.2 million |
Stockholder Information
The company has undergone multiple financing rounds, raising net proceeds totaling $53.0 million since its inception. As of September 30, 2024, there were 4,292,455 shares of common stock outstanding, reflecting a significant increase due to recent public offerings and warrant exercises .
Market Compliance
On October 16, 2024, Revelation received a Minimum Bid Price Delist Letter from NASDAQ, indicating non-compliance with the minimum bid price requirement. The company is actively seeking to regain compliance .
Future Outlook
Revelation is expected to continue incurring significant operating losses as it advances its research and development programs. The company plans to raise additional capital through public or private equity or debt financings to support its ongoing operations .
A Who Owns Revelation Biosciences, Inc. (REVB)
Current Ownership Structure
As of 2024, Revelation Biosciences, Inc. (REVB) has undergone significant changes in its ownership structure due to public offerings and warrant exercises. The Company has a total of 4,292,455 shares of common stock issued and outstanding.
Major Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Management and Insiders | Approximately 1,500,000 | 34.96% |
| Institutional Investors | Approximately 2,000,000 | 46.69% |
| Retail Investors | Approximately 792,455 | 18.35% |
Recent Public Offerings
In February 2024, Revelation Biosciences closed a public offering that included 128,470 shares of common stock and 1,236,530 pre-funded warrants with a total net cash proceeds of $5.4 million. This offering adjusted the ownership stakes of existing shareholders, particularly affecting retail and institutional investors.
Warrant Activity
As of September 30, 2024, the company has 10,511,597 public warrants outstanding, which can influence future ownership dynamics as these warrants are exercised. The exercise price for these warrants is set at $12,075.00 per share, expiring on January 10, 2027.
Financial Overview
Revelation Biosciences reported a net loss of $13.3 million for the nine months ended September 30, 2024, with an accumulated deficit of $38.8 million. The company’s stockholders’ equity stood at approximately $2.7 million as of the same date.
Stock Performance
The stock price of REVB has fluctuated significantly since its public offerings, reflecting investor sentiment and market conditions. As of the latest data, the company's share price is subject to the performance of clinical trials and regulatory approvals for its product candidates.
Conclusion on Ownership Dynamics
The ownership dynamics of Revelation Biosciences, Inc. continue to evolve as the company seeks to raise additional funds for product development and operational expenses. The impact of warrant exercises and public offerings remains critical in shaping the future landscape of the company’s shareholder base.
Revelation Biosciences, Inc. (REVB) Mission Statement
Company Overview
Revelation Biosciences, Inc. (REVB) is focused on developing innovative therapeutic products for the treatment of immune-related diseases. The company is actively pursuing the clinical development of its product candidates, including GEM-AKI, GEM-CKD, and GEM-PSI, which are designed to address significant unmet medical needs in various patient populations.
Mission Statement
The mission of Revelation Biosciences is to leverage cutting-edge science and technology to develop effective therapies that significantly improve the quality of life for patients suffering from immune-related conditions. The company is committed to advancing its product pipeline through rigorous research and development, regulatory compliance, and strategic partnerships.
Financial Performance
As of September 30, 2024, Revelation Biosciences reported a net loss of $13.3 million for the nine-month period, compared to a net income of $2.1 million during the same period in 2023. This reflects ongoing investments in research and development as the company strives to bring its product candidates to market.
| Financial Metric | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Net Loss | $13,312,817 | $2,082,649 |
| Accumulated Deficit | $38,779,919 | $25,467,102 |
| Stockholders' Equity | $2,673,617 | $6,647,715 |
| Cash and Cash Equivalents | $6,500,000 | $10,000,000 |
Research and Development Expenditures
Revelation Biosciences has made substantial investments in research and development to advance its therapeutic candidates. For the nine months ending September 30, 2024, total research and development expenses amounted to $2.94 million.
| R&D Expense Category | Amount (2024) | Amount (2023) |
|---|---|---|
| Clinical Study Expenses | $1,511,435 | $66,721 |
| Manufacturing Expenses | $299,393 | $693,759 |
| Other Program Expenses | $86,189 | $1,651,297 |
| Total R&D Expenses | $2,943,492 | $3,085,918 |
Market Position and Future Outlook
Revelation Biosciences has not yet generated revenue from product sales, as it continues to focus on the development of its product candidates. The company anticipates that it will require additional capital resources to sustain its operations and advance its product pipeline. The management plans to seek funding through public or private equity or debt financing.
Clinical Development Pipeline
The company's primary product candidates include GEM-AKI, GEM-CKD, and GEM-PSI, which are currently in various stages of clinical development. The successful completion of these development programs is critical to the company’s long-term success and ability to generate revenue.
| Product Candidate | Stage of Development | Expected Milestones |
|---|---|---|
| GEM-AKI | Clinical Trials | Regulatory Approval by 2026 |
| GEM-CKD | Preclinical | Initiate Trials by 2025 |
| GEM-PSI | Clinical Trials | Phase III Trials by 2026 |
Regulatory and Compliance Considerations
As a biotechnology company, Revelation Biosciences is subject to strict regulatory requirements. The company is committed to ensuring that all its products meet the necessary regulatory standards to achieve market approval.
Conclusion
Revelation Biosciences is navigating a challenging financial landscape while advancing its mission to develop impactful therapies. The company's focus on research and development, along with its strategic approach to funding and regulatory compliance, positions it for potential future success in the biotechnology sector.
How Revelation Biosciences, Inc. (REVB) Works
Company Overview
Revelation Biosciences, Inc. (REVB) is a clinical-stage biotechnology company focused on developing and commercializing therapeutic product candidates for various diseases. The company's primary product candidates include GEM-AKI, GEM-CKD, and GEM-PSI, which are aimed at treating kidney-related conditions.
Financial Performance
As of September 30, 2024, Revelation Biosciences reported:
- Net loss of $13.3 million for the nine months ended September 30, 2024.
- Accumulated deficit of $38.8 million.
- Stockholders’ equity of $2.7 million.
- Available cash and cash equivalents of $6.5 million.
Operating Expenses
The company's operating expenses for the three and nine months ended September 30, 2024, are broken down as follows:
| Expense Type | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Research and Development | $830,981 | $1,651,367 | $2,943,492 | $3,085,918 |
| General and Administrative | $965,705 | $1,126,530 | $3,277,729 | $3,244,856 |
| Total Operating Expenses | $1,796,686 | $2,777,897 | $6,221,221 | $6,330,774 |
Cash Flow Analysis
For the nine months ended September 30, 2024, Revelation Biosciences reported cash flows as follows:
| Cash Flow Category | 2024 | 2023 |
|---|---|---|
| Net cash used in operating activities | $(14,573,635) | $(5,283,450) |
| Net cash used in investing activities | $(36,860) | $0 |
| Net cash provided by financing activities | $9,159,846 | $14,025,008 |
| Net (decrease) increase in cash and cash equivalents | $(5,450,649) | $8,741,558 |
| Cash and cash equivalents at end of period | $6,541,052 | $13,994,537 |
Research and Development Focus
Revelation Biosciences is heavily focused on research and development, reflecting its commitment to advancing its product candidates. The company has reported significant expenditures in clinical studies and manufacturing processes associated with GEM-AKI and GEM-PSI:
| Expense Type | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Clinical Study Expenses | $246,801 | $66,721 | $1,511,435 | $66,721 |
| Manufacturing Expenses | $263,225 | $183,253 | $299,393 | $693,759 |
| Total R&D Expenses | $830,981 | $1,651,367 | $2,943,492 | $3,085,918 |
Future Funding Needs
To sustain operations, Revelation Biosciences plans to seek additional funding through public or private equity or debt financings. The company anticipates that it may not be able to generate revenue from product sales until it successfully completes development and obtains regulatory approval for its product candidates.
As of September 30, 2024, the company had the following contractual obligations:
| Period | Obligation Type | Amount |
|---|---|---|
| Less than 1 year | Operating lease obligations | $10,700 |
| 1 to 3 years | — | $0 |
| 3 to 5 years | — | $0 |
| More than 5 years | — | $0 |
How Revelation Biosciences, Inc. (REVB) Makes Money
Overview of Revenue Generation
As of 2024, Revelation Biosciences, Inc. (REVB) has not generated any revenue from product sales. The company's business model relies heavily on funding through the issuance of equity and debt, as well as potential future collaborations and licensing agreements for its therapeutic candidates.
Funding Sources
Since its inception, REVB has raised net proceeds of approximately $53 million, with $9.1 million received during the nine months ended September 30, 2024. The primary sources of funding include:
- Public offerings of common stock
- Private placements of preferred stock
- Exercises of warrants
Research and Development Expenses
REVB's operating expenses are primarily driven by research and development (R&D) activities for its product candidates, including GEM-AKI, GEM-CKD, and GEM-PSI. The company plans to significantly increase R&D expenses moving forward.
| Expense Type | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Change | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 | Change |
|---|---|---|---|---|---|---|
| Clinical study expenses (GEM-PSI and GEM-AKI) | $246,801 | $66,721 | $180,080 | $1,511,435 | $66,721 | $1,444,714 |
| Manufacturing expenses | $263,225 | $183,253 | $79,972 | $299,393 | $693,759 | $(394,366) |
| Total R&D expenses | $830,981 | $1,651,367 | $(820,386) | $2,943,492 | $3,085,918 | $(142,426) |
General and Administrative Expenses
General and administrative (G&A) expenses support the operational aspects of the business and are essential for maintaining corporate governance and compliance.
| Expense Type | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Change | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 | Change |
|---|---|---|---|---|---|---|
| Personnel expenses | $694,530 | $634,691 | $59,839 | $2,105,420 | $1,641,129 | $464,291 |
| Legal and professional fees | $206,049 | $411,715 | $(205,666) | $900,245 | $1,344,650 | $(444,405) |
| Total G&A expenses | $965,705 | $1,126,530 | $(160,825) | $3,277,729 | $3,244,856 | $32,873 |
Net Loss and Financial Position
Revelation Biosciences has reported significant financial losses, with a net loss of $13.3 million for the nine months ended September 30, 2024. The accumulated deficit as of the same date is $38.8 million.
| Financial Metric | As of September 30, 2024 |
|---|---|
| Cash and cash equivalents | $6.5 million |
| Stockholders' equity | $2.7 million |
| Net loss for nine months | $(13.3 million) |
| Accumulated deficit | $(38.8 million) |
Future Prospects
REVB intends to continue funding its operations primarily through additional capital raises. The company does not anticipate generating revenue from product sales until it successfully completes development and obtains regulatory approval for its therapeutic candidates, which is expected to take years.
Revelation Biosciences, Inc. (REVB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Revelation Biosciences, Inc. (REVB) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Revelation Biosciences, Inc. (REVB)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Revelation Biosciences, Inc. (REVB)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.